Crucell Falls Back on Vaccines
Forced by a series of setbacks to downsize its antibody platform, Crucell is now turning to vaccine applications of its human cell production technology to satisfy its product developer ambitions.
You may also be interested in...
Shire has been buffeted by management upheaval and generic and branded competition. But the group's foray into vaccines is a sensible long-term bet, offering it a low-risk route into R&D.
Sustainable and increasingly focused, mid-sized vaccines companies are leading the way in European biotech, catalyzed by fears of bioterrorism and a re-emerging belief that prevention trumps cure, both practically and pharmaco-economically.
J&J Centocor's deal with Crucell demonstrates how large pharma companies are being forced to make bigger sacrifices in return for potential products. Centocor is believed to be paying just $2 million, with $1-2 million in annual fees but the deal value could reach $100 million and give J&J an opportunity to strengthen its oncology product line. And Crucell gets closer to its goal of being a product company without taking on all the risks of drug development.